血漿分画の市場規模、シェア、成長分析、製品別、用途別、エンドユーザー別、地域別 - 産業予測 2025-2032年

血漿分画の世界市場規模は2023年に334億3,000万米ドルと評価され、2024年の362億米ドルから2032年には685億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.3％で成長する見通しです。

血漿分画の世界市場は、血漿由来の治療を必要とする希少疾患に罹患しやすくなっている高齢化社会を主な要因として、大きな成長が見込まれています。血漿分画は、血漿を分離して免疫グロブリンや第VIII因子などの重要な製品を製造するもので、血友病や免疫不全などの疾患の治療に欠かせないです。血漿採取施設の急増と並んで、これらの治療用途の普及率が上昇していることが、市場の拡大をさらに後押ししています。さらに、血漿由来製品に関する認知度向上を目指した政府の取り組みも市場力学に寄与しています。しかし、これらの血漿誘導体に関連する高コストが成長の課題となっており、ヘルスケアの現場における手頃な価格とアクセシビリティを高める戦略の必要性が浮き彫りになっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

血漿分画市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 免疫グロブリン
  • 静脈内免疫グロブリン
  • 皮下免疫グロブリン
  • その他の免疫グロブリン
• 凝固因子濃縮物
  • 第VIII因子
  • 第IX因子
  • フォン・ヴィレブランド因子
  • プロトロンビン複合体濃縮物
  • フィブリノゲン濃縮物
  • 第XIII因子
  • その他の凝固因子濃縮物
• アルブミン
• プロテアーゼ阻害剤
• その他の血漿製品

血漿分画市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 神経学
• 免疫学
• 血液学
• 集中治療
• 呼吸器科
• 血液腫瘍学
• リウマチ学
• その他の用途

血漿分画市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院と診療所
• 臨床調査ラボ
• 学術機関

血漿分画市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Grifols, S.A.（Spain）
• Takeda Pharmaceutical Company Limited（Japan）
• Octapharma AG（Switzerland）
• Kedrion S.p.A.（Italy）
• Biotest AG（Germany）
• LFB S.A.（France）
• Sanquin Blood Supply Foundation（Netherlands）
• China National Biotec Group Company Limited（China）
• ADMA Biologics, Inc.（USA）
• GC Biopharma Corp.（South Korea）
• Hualan Biological Bacterin Inc.（China）
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
• Shanghai RAAS Blood Products Co., Ltd.（China）

主な発展

• Bio Products Laboratory Ltd (UK)
• Green Cross Corporation (South Korea)
• TianTan Biological Products Corporation Limited (China)
• Emergent BioSolutions Inc. (USA)
• Kamada Ltd. (Israel)

結論と提言

Global Plasma Fractionation Market size was valued at USD 33.43 billion in 2023 and is poised to grow from USD 36.2 billion in 2024 to USD 68.52 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global plasma fractionation market is poised for significant growth, primarily driven by an aging population that is increasingly susceptible to rare diseases requiring plasma-derived treatments. Plasma fractionation involves separating blood plasma to produce vital products such as immunoglobulins and factor VIII, which are critical in treating conditions like hemophilia and immunological deficiencies. The rising prevalence of these therapeutic applications, alongside a surge in plasma collection facilities, further propels market expansion. Additionally, government initiatives aimed at increasing awareness about plasma-derived products are contributing to market dynamics. However, the high cost associated with these plasma derivatives poses a challenge to growth, underscoring the need for strategies that enhance affordability and accessibility in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segments Analysis

Global Plasma Fractionation Market is segmented by Product, Application, End User and region. Based on Product, the market is segmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Plasma Products. Based on Application, the market is segmented into Neurology, Immunology, Hematology, Critical care, Pulmonology, Hemato-Oncology, Rheumatology and Other Applications. Based on End User, the market is segmented into Hospitals and Clinics, Clinical Research Laboratories and Academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Plasma Fractionation Market

The increasing prevalence of diseases associated with immunodeficiency disorders and autoimmune conditions is a significant factor driving the expansion of the global plasma fractionation market. As healthcare professionals increasingly rely on immunoglobulins to treat these conditions, the demand for such products has surged. This rising demand not only propels growth in the market but also fosters innovation in the purification processes and manufacturing of plasma-derived therapeutic products. Consequently, this trend emphasizes the necessity for advancements in plasma fractionation technologies, further contributing to the development of effective treatments for patients suffering from these complex health issues.

Restraints in the Global Plasma Fractionation Market

The Global Plasma Fractionation market faces significant constraints stemming from the economic awareness of industry participants, which can lead to the establishment of barriers to entry in regions lacking support for economic growth. High costs associated with the plasma fractionation process, driven by sophisticated technology and stringent regulations, pose a challenge. These expenses create a barrier to market comprehension, particularly for smaller companies, hampering their potential for expansion. This situation is particularly pronounced in price-sensitive regions, where the financial burden can restrict participation and limit opportunities for development in the plasma fractionation sector.

Market Trends of the Global Plasma Fractionation Market

The global plasma fractionation market is witnessing significant growth driven by the surging demand for specialized plasma-derived products such as immunoglobulins and clotting factor concentrates. This trend is largely fueled by the rising prevalence of chronic and autoimmune diseases, prompting healthcare systems to seek more effective and targeted treatment solutions. Additionally, advancements in fractionation technologies and an expanding patient population are further propelling market expansion. As awareness of plasma-based therapies increases, stakeholders in this sector are investing in research and development to enhance product efficacy and safety, positioning the global plasma fractionation market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Plasma Fractionation Market Size by Product & CAGR (2025-2032)

• Market Overview
• Immunoglobulins
  • Intravenous Immunoglobulins
  • Subcutaneous Immunoglobulins
  • Other Immunoglobulins
• Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
  • Von Willebrand Factor
  • Prothrombin Complex Concentrate
  • Fibrinogen Concentrates
  • Factor XIII
  • Other Coagulation Factor Concentrates
• Albumin
• Protease Inhibitors
• Other Plasma Products

Global Plasma Fractionation Market Size by Application & CAGR (2025-2032)

• Market Overview
• Neurology
• Immunology
• Hematology
• Critical care
• Pulmonology
• Hemato-Oncology
• Rheumatology
• Other Applications

Global Plasma Fractionation Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Clinical Research Laboratories
• Academic institutes

Global Plasma Fractionation Market Size & CAGR (2025-2032)

• North America (Product, Application, End User)
  • US
  • Canada
• Europe (Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Blood Supply Foundation (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China National Biotec Group Company Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Biopharma Corp. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Bacterin Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates

Key Developments

• Bio Products Laboratory Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TianTan Biological Products Corporation Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations